(HealthDay News) – For patients with treatment-resistant obsessive-compulsive disorder (OCD), stereotactic anterior cingulotomy (SAC) may be a viable treatment option, according to a study presented at the annual meeting of the American Association of Neurological Surgeons (AANS), held from April 14–18 in Miami.
Sameer A. Sheth, MD, PhD, from Massachusetts General Hospital in Boston, and colleagues conducted a prospective study of 63 SAC procedures performed on patients with treatment-resistant OCD, from 1989–2010. Thirty-three patients underwent SAC alone and 30 underwent a subsequent procedure (repeat SAC or limbic leucotomy). Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and Beckman Depression Inventory (BDI) scores were obtained pre- and postoperatively. A ≥35% decrease in Y-BOCS was defined as a treatment response.
Based on follow-up data from 59 patients, the researchers found that 35% of the patients met the criteria for treatment response at the initial follow-up (mean, 11 months), while 48% met the criteria at the final follow-up (64 months). At the last follow-up, the mean decrease across all patients was 36% for Y-BOCS and 17% for BDI scores. Response status did not differ based on undergoing SAC alone versus additional procedures. Response was not predicted by age, gender, or type of obsessions or compulsions.
According to a press release from the AANS, “this study’s results, the largest series to date, demonstrate a 48% responder rate of SAC for treatment-refractory OCD with a greater than five-year follow-up. SAC is an effective, durable treatment alternative for patients suffering from severe OCD.”